Qube Research & Technologies LTD Myovant Sciences Ltd. Transaction History

Qube Research & Technologies LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$24.03 - $27.02 $9.61 Million - $10.8 Million	399,855 New	399,855 $10.8 Million
Q2 2022 Aug 15, 2022	SELL	$7.78 - $14.69 $116,606 - $220,173	-14,988 Closed	0 $0
Q1 2022 May 09, 2022	SELL	$11.38 - $16.4 $70,453 - $101,532	-6,191 Reduced 29.23%	14,988 $200,000
Q4 2021 Feb 01, 2022	BUY	$14.31 - $23.87 $303,071 - $505,542	21,179 New	21,179 $330,000
Q2 2021 Aug 13, 2021	SELL	$17.07 - $24.56 $175,052 - $251,862	-10,255 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$20.46 - $25.18 $209,817 - $258,220	10,255 New	10,255 $211,000
Q4 2020 Feb 16, 2021	SELL	$13.8 - $27.62 $611,284 - $1.22 Million	-44,296 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$14.05 - $22.6 $622,358 - $1 Million	44,296 New	44,296 $622,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.